Dose comparison of megavoltage cone-beam and orthogonal-pair portal images

Doses delivered by portal imaging quality assurance in routine practice of adjuvant breast radiotherapy worth to by monitored and compensated in some cases

Background

Imaging, in radiotherapy, has become a routine tool for repositioning of the target volume at each session. The repositioning precision, currently infracentimetric, evolves along with the irradiation techniques. This retrospective study aimed to identify practices and doses resulting from the use of high energy planar imaging (portal imaging) in daily practice.

Methods

A retrospective survey of portal images (PIs) was carried out over 10 years for 2,403 patients and for three linacs (1 Elekta SLi, 2 Varian Clinac) for postoperative mammary irradiations. Images were taken using a standardized number of monitor units (MU) for all patients. Due to the variable sensitivities of the detectors and the possibility of adjustment of the detector-patient distance, the number of MU were 3; 2 and 1 respectively, for Elekta SLi^®, Clinac 600^® and Clinac 2100^®. Then, a representative cumulated dose was calculated in simplified reference conditions (5 cm depth, beam of 10 cm × 10 cm, 6 MV), considering the total number of images taken during the whole treatment course. The consistency between the representative doses and the actual absorbed doses received by the patients was verified by simulating a series of typical cases with the treatment plan dose calculation system.

Results

The delivered doses differ significantly between the three linacs. The mean representative dose values by complete treatment were 0.695; 0.241 and 0.216 Gy, respectively, for SLi, Clinac 600 and Clinac 2100. However, 15 patients were exposed to a dose >2 Gy with a maximum dose of 5.05 Gy. The simulated doses were very similar to the representative doses.

Conclusions

A significant dose delivery was highlighted by this study. These representative doses are presently communicated weekly to the radiation oncologist for the radiation protection of their patients. Moreover, they should be taken into account in a possible study of long-term stochastic risks.

Comparison of prostate positioning guided by three-dimensional transperineal ultrasound and cone beam CT

OBJECTIVE

The accuracy of a transperineal three-dimensional ultrasound system (3DUS) was assessed for prostate positioning and compared to fiducial- and bone-based positioning in kV cone beam computed tomography (CBCT) during definitive radiotherapy of prostate cancer.

METHODS

Each of the 7 patients had three fiducial markers implanted into the prostate before treatment. Prostate positioning was simultaneously measured by 3DUS and CBCT before each fraction. In total, 177 pairs of 3DUS and CBCT scans were collected. Bone-match and seed-match were performed for each CBCT. Using seed-match as a reference, the accuracy of 3DUS and bone-match was evaluated. Systematic and random errors as well as optimal setup margins were calculated for 3DUS and bone-match.

RESULTS

The discrepancy between 3DUS and seed-match in CBCT (average ± standard deviation) was 0.0 ± 1.7 mm laterally, 0.2 ± 2.0 mm longitudinally, and 0.3 ± 1.7 mm vertically. Using seed-match as a reference, systematic errors for 3DUS were 1.2 mm, 1.1 mm, and 0.9 mm; and random errors were 1.4 mm, 1.8 mm, and 1.6 mm, on lateral, longitudinal, and vertical axes, respectively. By analogy, the difference of bone-match to seed-match was 0.1 ± 1.1 mm laterally, 1.3 ± 3.8 mm longitudinally, and 1.3 ± 4.5 mm vertically. Systematic errors were 0.5 mm, 2.2 mm, and 2.6 mm; and random errors were 1.0 mm, 3.1 mm, and 3.9 mm on lateral, longitudinal, and vertical axes, respectively. The accuracy of 3DUS was significantly higher than that of bone-match on longitudinal and vertical axes, but not on the lateral axis.

CONCLUSION

Image-guided radiotherapy of prostate cancer based on transperineal 3DUS was feasible, with overall small discrepancy to seed-match in CBCT in this retrospective study. Compared to bone-match, transperineal 3DUS achieved higher accuracy on longitudinal and vertical axes.

Imaging dose from cone beam computed tomography in radiation therapy

Imaging dose in radiation therapy has traditionally been ignored due to its low magnitude and frequency in comparison to therapeutic dose used to treat patients. The advent of modern, volumetric, imaging modalities, often as an integral part of linear accelerators, has facilitated the implementation of image-guided radiation therapy (IGRT), which is often accomplished by daily imaging of patients. Daily imaging results in additional dose delivered to patient that warrants new attention be given to imaging dose. This review summarizes the imaging dose delivered to patients as the result of cone beam computed tomography (CBCT) imaging performed in radiation therapy using current methods and equipment. This review also summarizes methods to calculate the imaging dose, including the use of Monte Carlo (MC) and treatment planning systems (TPS). Peripheral dose from CBCT imaging, dose reduction methods, the use of effective dose in describing imaging dose, and the measurement of CT dose index (CTDI) in CBCT systems are also reviewed.

Imaging dose in breast radiotherapy: does breast size affect the dose to the organs at risk and the risk of secondary cancer to the contralateral breast?

Introduction

Correct target positioning is crucial for accurate dose delivery in breast radiotherapy resulting in utilisation of daily imaging. However, the radiation dose from daily imaging is associated with increased probability of secondary induced cancer. The aim of this study was to quantify doses associated with three imaging modalities and investigate the correlation of dose and varying breast size in breast radiotherapy.

Methods

Planning computed tomography (CT) data sets of 30 breast cancer patients were utilised to simulate the dose received by various organs from a megavoltage computed tomography (MV-CT), megavoltage electronic portal image (MV-EPI) and megavoltage cone-beam computed tomography (MV-CBCT). The mean dose to organs adjacent to the target volume (contralateral breast, lungs, spinal cord and heart) were analysed. Pearson correlation analysis was performed to determine the relationship between imaging dose and primary breast volume and the lifetime attributable risk (LAR) of induced secondary cancer was calculated for the contralateral breast.

Results

The highest contralateral breast mean dose was from the MV-CBCT (1.79 Gy), followed by MV-EPI (0.22 Gy) and MV-CT (0.11 Gy). A similar trend was found for all organs at risk (OAR) analysed. The primary breast volume inversely correlated with the contralateral breast dose for all three imaging modalities. As the primary breast volume increases, the likelihood of a patient developing a radiation-induced secondary cancer to the contralateral breast decreases. MV-CBCT showed a stronger relationship between breast size and LAR of developing a radiation-induced contralateral breast cancer in comparison with the MV-CT and MV-EPI.

Conclusions

For breast patients, imaging dose to OAR depends on imaging modality and treated breast size. When considering the use of imaging during breast radiotherapy, the patient's breast size and contralateral breast dose should be taken into account.

Interfractional variability in intensity-modulated radiotherapy of prostate cancer with or without thermoplastic pelvic immobilization

PURPOSE

To determine the variability of patient positioning errors associated with intensity-modulated radiotherapy (IMRT) for prostate cancer and to assess the impact of thermoplastic pelvic immobilization on these errors using kilovoltage (kV) cone-beam computed tomography (CBCT).

MATERIALS AND METHODS

From February 2012 to June 2012, the records of 314 IMRT sessions in 19 patients with prostate cancer, performed with or without immobilization at two different facilities in the Korea University Hospital were analyzed. The kV CBCT images were matched to simulation computed tomography (CT) images to determine the simulation-to-treatment variability. The shifts along the x (lateral)-, y (longitudinal)- and z (vertical)-axes were measured, as was the shift in the three dimensional (3D) vector.

RESULTS

The measured systematic errors in the immobilized group during treatment were 0.46 ± 1.75 mm along the x-axis, - 0.35 ± 3.83 mm along the y-axis, 0.20 ± 2.75 mm along the z-axis and 4.05 ± 3.02 mm in the 3D vector. Those of nonimmobilized group were - 1.45 ± 7.50 mm along the x-axis, 1.89 ± 5.07 mm along the y-axis, 0.28 ± 3.81 mm along the z-axis and 8.90 ± 4.79 mm in the 3D vector. The group immobilized with pelvic thermoplastics showed reduced interfractional variability along the x- and y-axes and in the 3D vector compared to the nonimmobilized group (p < 0.05).

CONCLUSION

IMRT with thermoplastic pelvic immobilization in patients with prostate cancer appears to be useful in stabilizing interfractional variability during the planned treatment course.

Dosimetric comparison of patient setup strategies in stereotactic body radiation therapy for lung cancer

PURPOSE

In this work, the authors retrospectively compared the accumulated dose over the treatment course for stereotactic body radiation therapy (SBRT) of lung cancer for three patient setup strategies.

METHODS

Ten patients who underwent lung SBRT were selected for this study. At each fraction, patients were immobilized using a vacuum cushion and were CT scanned. Treatment plans were performed on the simulation CT. The planning target volume (PTV) was created by adding a 5-mm uniform margin to the internal target volume derived from the 4DCT. All plans were normalized such that 99% of the PTV received 60 Gy. The plan parameters were copied onto the daily CT images for dose recalculation under three setup scenarios: skin marker, bony structure, and soft tissue based alignments. The accumulated dose was calculated by summing the dose at each fraction along the trajectory of a voxel over the treatment course through deformable image registration of each CT with the planning CT. The accumulated doses were analyzed for the comparison of setup accuracy.

RESULTS

The tumor volume receiving 60 Gy was 91.7 ± 17.9%, 74.1 ± 39.1%, and 99.6 ± 1.3% for setup using skin marks, bony structures, and soft tissue, respectively. The isodose line covering 100% of the GTV was 55.5 ± 7.1, 42.1 ± 16.0, and 64.3 ± 7.1 Gy, respectively. The corresponding average biologically effective dose of the tumor was 237.3 ± 29.4, 207.4 ± 61.2, and 258.3 ± 17.7 Gy, respectively. The differences in lung biologically effective dose, mean dose, and V20 between the setup scenarios were insignificant.

CONCLUSIONS

The authors' results suggest that skin marks and bony structure are insufficient for aligning patients in lung SBRT. Soft tissue based alignment is needed to match the prescribed dose delivered to the tumors.

Impact of different CBCT imaging monitor units, reconstruction slice thicknesses, and planning CT slice thicknesses on the positioning accuracy of a MV-CBCT system in head-and-neck patients

The purpose of this study was to investigate the impact of different CBCT imaging monitor units (MUs), reconstruction slice thicknesses, and planning CT slice thicknesses on the positioning accuracy of a megavoltage cone-beam computed tomography (MV-CBCT) system in image-guided radiation therapy (IGRT) in head-and-neck patients. The MV-CBCT system was a Siemens MVision, a commercial system integrated into the Siemens ONCOR linear accelerator. The positioning accuracy of the MV-CBCT system was determined using an anthropomorphic phantom while varying the MV-CBCT imaging MU, reconstruction slice thickness, and planning CT slice thickness. A total of 240 CBCT images from six head-and-neck patients who underwent intensity-modulated radiotherapy (IMRT) treatment were acquired and reconstructed using different MV-CBCT scanning protocols. The interfractional setup errors of the patients were retrospectively analyzed for different imaging MUs, reconstruction slice thicknesses, and planning CT slice thicknesses. Using the anthropomorphic phantom, the largest measured mean deviation component and standard deviation of the MVision in 3D directions were 1.3 and 1.0 mm, respectively, for different CBCT imaging MUs, reconstruction slice thicknesses, and planning CT slice thicknesses. The largest setup group system error (M), system error (Σ), and random error (σ) from six head-and-neck patients were 0.6, 1.2, and 1.7 mm, respectively. No significant difference was found in the positioning accuracy of the MV-CBCT system between the 5 and 8 MUs, and between the 1 and 3 mm reconstruction slice thicknesses. A thin planning CT slice thickness may achieve higher positioning precision using the phantom measurement, but no significant difference was found in clinical setup precision between the 1 and 3 mm planning CT slice thicknesses.

Peripheral dose from megavoltage cone-beam CT imaging for nasopharyngeal carcinoma image-guided radiation therapy

The growing use of cone-beam computed tomography (CBCT) for IGRT has increased concerns over the additional radiation dose to patients. The in-field dose of IGRT and the peripheral dose (PD) from kilovoltage CBCT (KV-CBCT) imaging have been well quantified. The purpose of this work is to evaluate the peripheral dose from megavoltage CBCT (MV-CBCT) imaging for nasopharyngeal carcinoma IGRT, to determine the correlation of peripheral dose with MU protocol and imaging field size, and to estimate out-of-field organ-at-risk (OAR) dose delivered to patients. Measurements of peripheral MV-CBCT doses were made with a 0.65 cm(3) ionization chamber placed inside in a specially designed phantom at various depths and distances from the imaging field edges. The peripheral dose at reference point inside the phantom was measured with the same ionization chamber to investigate the linearity between MUs used for MV-CBCT imaging and the PD. The peripheral surface doses at the anterior, lateral, and posterior of the phantom at various distances from the imaging field edge were also measured with thermoluminescent dosimeters (TLDs). Seven nasopharyngeal carcinoma patients were selected and scanned before treatment with head-neck protocol, and the peripheral surface doses were measured with TLDs placed on the anterior, lateral, and posterior surfaces at the axial plane of 15 cm distance from the field edge. The measured peripheral doses data in the phantom were utilized to estimate the peripheral OAR dose. Peripheral dose from MV-CBCT imaging increased with increasing number of MUs used for imaging protocol and with increasing the imaging field size. The measured peripheral doses in the phantom decreased as distance from the imaging field edges increased. PD also decreased as the depth from the phantom surface increased. For the patient PD measurements, the anterior, lateral, and posterior surface doses of 15 cm distance from the field edge were 2.84 × 10(-2), 1.01 × 10(-2), and 0.78 × 10(-2) cGy/MU, respectively. The lens, thyroid, breast, and ovary and testicle, which are outside the treatment and imaging fields, were estimated to receive peripheral OAR doses from MV-CBCT imaging of 42.4 × 10(-2), 11.9 × 10(-2), 1.4 × 10(-2), 1.0 × 10(-2), and 0.5 × 10(-2) cGy/MU, respectively. In conclusion, MV-CBCT generates a peripheral dose beyond the edge of the MV-CBCT scanning field that is of a similar order of magnitude to the peripheral dose from kV-CBCT imaging. In clinic, using the smallest number of MUs allowable and reducing MV-CBCT scanning field size without compromising acquired image quality is an effective method of reducing the peripheral OAR dose received by patients.

Radiation dose and contralateral breast cancer risk associated with megavoltage cone-beam computed tomographic image verification in breast radiation therapy

PURPOSE

To measure and compare organ doses from a standard tangential breast radiation therapy treatment (50 Gy delivered in 25 fractions) and a megavoltage cone-beam computed tomography (MV-CBCT), taken for weekly image verification, and assess the risk of radiation-induced contralateral breast cancer.

METHODS AND MATERIALS

Organ doses were measured with thermoluminescent dosimeters placed strategically within a female anthropomorphic phantom. The risk of radiation-induced secondary cancer of the contralateral breast was estimated from these values using excess absolute risk and excess relative risk models.

RESULTS

The effective dose from a MV-CBCT (8-monitor units) was 35.9 ± 0.2 mSv. Weekly MV-CBCT imaging verification contributes 0.5% and 17% to the total ipsilateral and contralateral breast dose, respectively. For a woman irradiated at age 50 years, the 10-year postirradiation excess relative risk was estimated to be 0.8 and 0.9 for treatment alone and treatment plus weekly MV-CBCT imaging, respectively. The 10-year postirradiation excess absolute risk was estimated to be 4.7 and 5.6 per 10,000 women-years.

CONCLUSIONS

The increased dose and consequent radiation-induced second cancer risk as calculated by this study introduced by the imaging verification protocols utilizing MV-CBCT in breast radiation therapy must be weighed against the benefits of more accurate treatment. As additional image verification becomes more common, it is important that data be collected in regard to long-term malignancy risk.

Influence of acquisition parameters on MV-CBCT image quality

The production of high quality pretreatment images plays an increasing role in image‐guided radiotherapy (IGRT) and adaptive radiation therapy (ART). Megavoltage cone‐beam computed tomography (MV‐CBCT) is the simplest solution of all the commercially available volumetric imaging systems for localization. It also suffers the most from relatively poor contrast due to the energy range of the imaging photons. Several avenues can be investigated to improve MV‐CBCT image quality while maintaining an acceptable patient exposure: beam generation, detector technology, reconstruction parameters, and acquisition parameters. This article presents a study of the effects of the acquisition scan length and number of projections of a Siemens Artiste MV‐CBCT system on image quality within the range provided by the manufacturer. It also discusses other aspects not related to image quality one should consider when selecting an acquisition protocol. Noise and uniformity were measured on the image of a cylindrical water phantom. Spatial resolution was measured using the same phantom half filled with water to provide a sharp water/air interface to derive the modulation transfer function (MTF). Contrast‐to‐noise ratio (CNR) was measured on a pelvis‐shaped phantom with four inserts of different electron densities relative to water (1.043, 1.117, 1.513, and 0.459). Uniformity was independent of acquisition protocol. Noise decreased from 1.96% to 1.64% when the total number of projections was increased from 100 to 600 for a total exposure of 13.5 MU. The CNR showed a∓5% dependence on the number of projections and 10% dependence on the scan length. However, these variations were not statistically significant. The spatial resolution was unaffected by the arc length or the sampling rate. Acquisition parameters have little to no effect on the image quality of the MV‐CBCT system within the range of parameters available on the system. Considerations other than image quality, such as memory storage, acquisition speed, and individual projection image quality, speak in favor of the use of a coarse sampling rate on the short scan.

PACS numbers: 87.57.C‐; 87.57.nf

Prostate image-guided radiotherapy by megavolt cone-beam CT

PURPOSE

To test megavolt cone-beam CT (MV-CBCT) in order to evaluate setup errors in prostate radiotherapy.

PATIENTS AND METHODS

The setup of 9 patients was verified weekly by electronic portal imaging (EPI) and MV-CBCT, both per-formed in the same treatment session. EPI were compared with digitally reconstructed radiographies (DRRs). MV-CBCTs were matched to simulation CTs by manual registration based on bone markers (BMR), by manual registration based on soft tissues (STR) - rectum, bladder, and seminal vesicles - and by automatic registration (AR) performed by a mutual information algorithm. Shifts were evaluated along the three main axes: anteroposterior (AP), craniocaudal (CC), and laterolateral (LL). Finally, in 4 additional patients showing intraprostatic calcifications, the calcification mismatch error was used to evaluate the three MV-CBCT matching methods.

RESULTS

A total of 50 pairs of orthogonal EPIs and 50 MV-CBCTs were analyzed. Assuming an overall tolerance of 2 mm, no significant differences were observed comparing EPI vs BMR in any axis. A significant difference (p < 0.001) was observed along the AP axis comparing EPI vs AR and EPI vs STR. On the calcification data set (22 measures), the calcification mismatch along the AP direction was significantly lower (p < 0.05) after STR than after BMR or AR.

CONCLUSION

Bone markers were not an effective surrogate of the target position and significant differences were observed comparing EPI or BMR vs STR, supporting the assessment of soft tissue position by MVCBs to verify and correct patient setup in prostate radiotherapy.

Megavoltage cone beam computed tomography dose and the necessity of reoptimization for imaging dose-integrated intensity-modulated radiotherapy for prostate cancer

PURPOSE

Megavoltage cone beam computed tomography (MV-CBCT) dose can be integrated with the patient's prescription. Here, we investigated the effects of imaging dose and the necessity for additional optimization when using intensity-modulated radiotherapy (IMRT) to treat prostate cancer.

METHODS AND MATERIALS

An arc beam mimicking MV-CBCT was generated using XiO (version 4.50; Elekta, Stockholm, Sweden). The monitor units (MU) for dose calculation were determined by conforming the calculated dose to the dose measured using an ionization chamber. IMRT treatment plans of 22 patients with prostate cancer were retrospectively analyzed. Arc beams of 3, 5, 8, and 15 MU were added to the IMRT plans, and the dose covering 95% of the planning target volume (PTV) was normalized to the prescribed dose with (reoptimization) or without optimization (compensation).

RESULTS

PTV homogeneity and conformality changed negligibly with MV-CBCT integration. For critical organs, an imaging dose-dependent increase was observed for the mean rectal/bladder dose (D(mean)), and reoptimization effectively suppressed the D(mean) elevations. The bladder generalized equivalent uniform dose (gEUD) increased with imaging dose, and reoptimization suppressed the gEUD elevation when 5- to 15-MU CBCT were added, although rectal gEUD changed negligibly with any imaging dose. Whereas the dose elevation from the simple addition of the imaging dose uniformly increased rectal and bladder dose, the rectal D(mean) increase of compensation plans was due mainly to low-dose volumes. In contrast, bladder high-dose volumes were increased by integrating the CBCT dose, and reoptimization reduced them when 5- to 15-MU CBCT were added.

CONCLUSION

Reoptimization is clearly beneficial for reducing dose to critical organs, elevated by addition of high-MU CBCT, especially for the bladder. For low-MU CBCT aimed at bony structure visualization, compensation is sufficient.

Dosimetry challenges for implementing emerging technologies

During the last 10 years, radiation therapy technologies have gone through major changes, mainly related introduction of sophisticated delivery and imaging techniques to improve the target localization accuracy and dose conformity. While implementation of these emerging technologies such as image-guided SRS/SBRT, IMRT/IMAT, IGRT, 4D motion management, and special delivery technologies showed substantial clinical gains for patient care, many other factors, such as training/quality, efficiency/efficacy, and cost/effectiveness etc. remain to be challenging. This talk will address technical challenges for dosimetry verification of implementing these emerging technologies in radiation therapy.

[IMRT combined to IGRT: increase of the irradiated volume. Consequences?]

Image-guided radiotherapy (IGRT) combined or not with intensity-modulated radiation therapy (IMRT) are new and very useful techniques. However, these new techniques are responsible of irradiation at low dose in large volumes. The control of alignment, realignment of the patient and target positioning in external beam radiotherapy are increasingly performed by radiological imaging devices. The management of this medical imaging depends on the practice of each radiotherapy centre. The physical doses due to the IGRT are however quantifiable and traceable. In one hand, these doses appear justified for a better targeting and could be considered negligible in the context of radiotherapy. On the other hand, the potential impact of these low doses should deserve the consideration of professionals. It appears important therefore to report and consider not only doses in target volumes and in "standard" organs at risk, but also the volume of all tissue receiving low doses of radiation. The recent development of IMRT launches the same issue concerning the effects of low doses of radiation. Indeed, IMRT increases the volume of healthy tissue exposed to radiation. At low dose (<100mGy), many parameters have to be considered for health risk estimations: the induction of genes and activation of proteins, bystander effect, radio-adaptation, the specific low-dose radio-hypersensitivity and individual radiation sensitivity. With the exception of the latter, the contribution of these parameters is generally protective in terms of carcinogenesis. An analysis of secondary cancers arising out of field appears to confirm such notion. The risk of secondary tumours is not well known in these conditions of treatment associating IMRT and IGRT. It is therefore recommended that the dose due to imaging during therapeutic irradiation be reported.

Image quality & dosimetric property of an investigational imaging beam line MV-CBCT

To measure and compare the contrast to noise ratio (CNR) as a function of dose for the CBCTs produced by the mega‐voltage (MV) imaging beam line (IBL) and the treatment beam line (TBL), and to compare the dose to target and various critical structures of pediatric patients for the IBL CBCT versus standard TBL orthogonal port films.

Two Siemens Oncor linear accelerators were modified at our institution such that the MV‐CBCT would operate under an investigational IBL rather than the standard 6MV TBL. Prior to the modification, several CBCTs of an electron density phantom were acquired with the TBL at various dose values. After the modification, another set of CBCTs of the electron density phantom were acquired for various doses using the IBL. The contrast to noise ratio (CNR) for each tissue equivalent insert was calculated. In addition, a dosimetric study of pediatric patients was conducted comparing the 1 cGy IBL CBCT and conventional TBL orthogonal pair port films.

The CNR for eight tissue equivalent inserts at five different dose settings for each type of CBCT was measured. The CNR of the muscle insert was 0.8 for a 5 cGy TBL CBCT, 1.1 for a 1.5 cGy IBL CBCT, and 2.8 for a conventional CT. The CNR of the trabecular bone insert was 2.9 for a 5 cGy TBL CBCT, 5.5 for a 1.5 cGy IBL CBCT, and 14.8 for a conventional CT. The IBL CBCT delivered approximately one‐fourth the dose to the target and critical structures of the patients as compared to the TBL orthogonal pair port films.

The IBL CBCT improves image quality while simultaneously reducing the dose to the patient as compared to the TBL CBCT. A 1 cGy IBL CBCT, which is used for bony anatomy localization, delivers one‐fourth the dose as compared to conventional ortho‐pair films.

PACS number: 87.57.Q, 87.57.cj, 87.53.Jw

Radiation therapy for children: evolving technologies in the era of ALARA

The evolution of ever more sophisticated oncologic imaging and technologies providing far more precise radiation therapy have combined to increase the utilization of sophisticated radiation therapy in childhood cancer. For a majority of children with common central nervous system, soft tissue, bone, and dysontogenic neoplasms, local irradiation is fundamental to successful multi-disciplinary management. Along with more precise target volume definition and radiation delivery, new technologies provide added certainty of patient positioning (electronic portal imaging, cone beam CT) and conformality of dose delivery (3-D conformal irradiation, intensity modulated radiation therapy, proton beam therapy). Each of the major areas of technology development are able to better confine the high-dose region to the intended target, but they are also associated with the potential for larger volumes of uninvolved tissues being exposed to low radiation doses. The latter issue plays a role in documented levels of secondary carcinogenesis, sometimes with greater anticipated incidence than that seen in conventional radiation therapy. Parameters related to carcinogenesis, such as dose-volume relationships and neutron contamination that accompanies high-energy photon irradiation and proton therapy, can be identified, sometimes modulated, and accepted as part of the clinical decision process in fine tuning radiation therapy in this more vulnerable age group.

Assessment of patient organ doses and effective doses using the VIP-Man adult male phantom for selected cone-beam CT imaging procedures during image guided radiation therapy

A Monte Carlo based computational procedure for determining organ doses and effective doses has been described for two procedures used in newly developed image-guided radiation treatment: kilovoltage cone-beam computed tomography (kV CBCT) and mega-voltage computed tomography (MV CBCT). A whole-body patient computational phantom, VIP-Man phantom, is employed for Monte Carlo dose calculations. Results indicate that the thyroid dose is always the highest in head and neck (H&N) scan for both kV and MV CBCT, and the bladder dose is the highest in prostate scan for both kV and MV CBCT. For the VIP-Man phantom, it has been found that the effective dose for kV CBCT (assuming a total exposure of 1350 mAs) is approximately 9.5 mSv for the two anatomical sites, whereas the effective dose for MV CBCT (assuming a total of 6 monitor unit) ranges from 5.10 mSv for the H&N case to 8.39 mSv for the prostate scan. The estimated whole-body effective doses allow different imaging procedures to be compared and evaluated.

Radiothérapie guidée par l'image

Recent advances in radiation oncology are based on improvement in dose distribution thanks to IMRT and improvement in target definition through new diagnostic imaging such as spectroscopic or functional MRI or PET. However, anatomic variations may occur during treatment decreasing the benefit of such optimization. Image-guided radiotherapy reduces geometric uncertainties occurring during treatment and therefore should reduce dose delivered to healthy tissues and enable dose escalation to enhance tumour control. However, IGRT experience is still limited, while a wide panel of IGRT modalities is available. A strong quality control is required for safety and proper evaluation of the clinical benefit of IGRT combined or not with IMRT.